



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
production.office@frontiersin.org

SPECIALTY SECTION  
This article was submitted to  
Cancer Immunity  
and Immunotherapy,  
a section of the journal  
Frontiers in Immunology

RECEIVED 27 July 2022  
ACCEPTED 27 July 2022  
PUBLISHED 11 August 2022

CITATION  
Frontiers Production Office (2022)  
Erratum: Development of  
immunotherapy strategies targeting  
tumor microenvironment is fiercely  
ongoing.  
*Front. Immunol.* 13:1004587.  
doi: 10.3389/fimmu.2022.1004587

COPYRIGHT  
© 2022 Frontiers Production Office. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction  
in other forums is permitted, provided  
the original author(s) and the  
copyright owner(s) are credited and  
that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Erratum: Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

cancer, tumor microenvironment, immunotherapy, inhibitory signaling, stimulatory signaling

## An Erratum on

**Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing**

by Bai R and Cui J (2022). *Front. Immunol.* 13:890166. doi: 10.3389/fimmu.2022.890166

Due to a production error, there were inaccuracies in the section numbering. The corrected subsection numbering should read as follows:

1. Introduction
2. Immunotherapeutic Strategies Targeting the TME
  - 2.1 Therapeutic Strategies Based on TME Inhibitory Signaling
    - 2.1.1 Targeting TME Physical Barriers
    - 2.1.2 Targeting Immune Checkpoints
    - 2.1.3 Targeting Immunosuppressive Cells
    - 2.1.4 Targeting Inhibitory Cytokines
    - 2.1.5 Targeting Metabolic Inhibition Signaling
  - 2.2 Therapeutic Strategies Based on TME Stimulatory Signals
    - 2.2.1 Targeting Stimulatory Checkpoints
    - 2.2.2 Application of Stimulating Cytokines
    - 2.2.3 Enhancing Antigen Presentation
    - 2.2.4 Application of Immune Effector cells
3. Challenges Faced by Time Research and Solutions
  - 3.1 Complexity of TIME
  - 3.2 Spatiotemporal Heterogeneity of TIME
  - 3.3 Systemic Immunity Affects TME Immune Response
4. Summary and Prospect

The publisher apologizes for this mistake.

The original version of this article has been updated.